Vanguard Group Inc. Increases Holdings in Aveanna Healthcare Holdings Inc. $AVAH

Vanguard Group Inc. increased its stake in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) by 38.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,577,010 shares of the company’s stock after purchasing an additional 1,535,351 shares during the quarter. Vanguard Group Inc.’s holdings in Aveanna Healthcare were worth $45,564,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in AVAH. AQR Capital Management LLC grew its position in shares of Aveanna Healthcare by 21.2% in the first quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock valued at $142,000 after purchasing an additional 4,602 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Aveanna Healthcare by 8.3% in the first quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock valued at $1,842,000 after purchasing an additional 25,974 shares in the last quarter. Jane Street Group LLC grew its position in shares of Aveanna Healthcare by 522.0% in the first quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock valued at $407,000 after purchasing an additional 63,010 shares in the last quarter. Creative Planning grew its position in shares of Aveanna Healthcare by 15.1% in the second quarter. Creative Planning now owns 47,025 shares of the company’s stock valued at $246,000 after purchasing an additional 6,171 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Aveanna Healthcare by 65.0% in the second quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock valued at $828,000 after purchasing an additional 62,348 shares in the last quarter. 87.96% of the stock is currently owned by hedge funds and other institutional investors.

More Aveanna Healthcare News

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Aveanna reported Q1 2026 EPS of $0.18, topping the $0.13 consensus estimate, while revenue came in at $647.9 million versus expectations of $613.2 million. Article Title
• Positive Sentiment: The company raised 2026 revenue guidance to $2.56 billion-$2.58 billion and adjusted EBITDA guidance to $328 million-$332 million, signaling management sees continued momentum ahead. Article Title
• Positive Sentiment: Stephens upgraded AVAH from “equal weight” to “overweight” and increased its price target to $11, reflecting improved confidence in the stock’s outlook. Article Title
• Positive Sentiment: Royal Bank of Canada also raised its price target on AVAH to $10 from $9, adding to the generally favorable analyst response after earnings. Article Title
• Neutral Sentiment: Recent earnings-call transcripts and recap articles largely repeated the same message: strong quarterly results, revenue growth, and improved guidance, reinforcing the bullish narrative but not adding new catalysts. Article Title

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Royal Bank Of Canada lifted their price objective on Aveanna Healthcare from $9.00 to $10.00 and gave the company a “sector perform” rating in a research note on Friday. Weiss Ratings lowered Aveanna Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $10.00 to $11.00 in a research note on Friday. BMO Capital Markets dropped their price objective on Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, March 20th. Finally, Zacks Research lowered Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.44.

Aveanna Healthcare Trading Up 3.8%

Shares of AVAH stock opened at $7.72 on Friday. The stock has a market capitalization of $1.68 billion, a PE ratio of 6.54 and a beta of 1.93. Aveanna Healthcare Holdings Inc. has a 1-year low of $3.73 and a 1-year high of $10.32. The business has a 50-day moving average of $6.71 and a 200 day moving average of $7.92. The company has a debt-to-equity ratio of 6.62, a current ratio of 1.32 and a quick ratio of 1.32.

Aveanna Healthcare (NASDAQ:AVAH) last issued its earnings results on Thursday, May 14th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.05. The company had revenue of $647.92 million during the quarter, compared to analysts’ expectations of $613.22 million. Aveanna Healthcare had a return on equity of 210.63% and a net margin of 10.37%.The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.56 earnings per share for the current year.

Insider Activity at Aveanna Healthcare

In related news, CFO Matthew Buckhalter sold 13,512 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $7.21, for a total transaction of $97,421.52. Following the completion of the sale, the chief financial officer directly owned 529,243 shares in the company, valued at $3,815,842.03. This represents a 2.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Deborah Stewart sold 11,181 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $80,615.01. Following the sale, the chief accounting officer owned 301,807 shares of the company’s stock, valued at $2,176,028.47. This represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 738,957 shares of company stock worth $5,458,175 over the last three months. Corporate insiders own 5.30% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.